Removing Neumann is a difficult decision for Son, who has long believed in WeWork and Neumann's vision to quickly expand the company.Technologyread more
The next three weeks are among the rockiest, on a historical basis, of the entire calendar.Trading Nationread more
Of all the cases of economic espionage charged by the DOJ's National Security Division since 2012, more than 80% of them implicated China.World Politicsread more
In his new memoir, "The Ride of a Lifetime," Iger explains why he decided against the deal to buy Twitter.Technologyread more
Ad-tech company The Trade Desk is launching a campaign to show how it differs from tech giants like Google and Facebook.Technologyread more
The streaming wars may have claimed a new victim, and one technical analyst says it could be about to get worse.Trading Nationread more
"Whilst there is a big dispute at the moment, I think there's also potential for resolution," UBS chairman Axel Weber says of the U.S.-China trade negotiations.Singapore Summitread more
No quid pro quo, there was nothing," Trump said the call. "It was a perfect conversation."Politicsread more
On Sunday, the 71st Primetime Emmy Awards honored the best comedies, dramas, limited and variety series from the last year.Entertainmentread more
The UK's Civil Aviation Authority said Thomas Cook had now ceased trading and the regulator would work with the government to bring the more than 150,000 British customers...Europe Marketsread more
Cryptocurrency fans will hope the futures contracts, which are federally regulated, can provide some much-needed legitimacy to bitcoin.Cryptocurrencyread more
India-based generic drugmaker Ranbaxy Laboratories has issued a recall of generic versions of the cholesterol drug Lipitor in the U.S. because of potential dosage issues, The Wall Street Journal reported Friday.
The company recalled more than 64,000 bottles of 10-milligram tablets of atorvastatin calcium—the active ingredient in Lipitor—saying some bottles could possibly contain a higher dose, the U.S. Food and Drug Administration said in a note.
Ranbaxy confirmed the recall on Friday, noting that the recall started in mid-January. Notice of the recall was posted on the FDA's website this week.
The company, which makes ingredients for drugs used in oncology, dermatology, gastrointestinal and cardiovascular disorders, generated 36 percent of its sales in the U.S. in the quarter ended in December.
Last month, Ranbaxy suspended shipments of pharmaceutical ingredients from two plants amid growing scrutiny of its manufacturing processes by regulators.
The suspension affected supplies to other key markets such as Europe and India, two people with direct knowledge of the matter said.
—By CNBC with Reuters.